Aridis shares are trading higher after the company announced FDA Qualified Infectious Disease Product Designation for AR-301.
Portfolio Pulse from Benzinga Newsdesk
Aridis Pharmaceuticals has received FDA Qualified Infectious Disease Product Designation for its product AR-301, leading to a rise in its share prices.
July 12, 2023 | 12:17 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Aridis Pharmaceuticals' stock is trading higher following the FDA's Qualified Infectious Disease Product Designation for AR-301.
The FDA's Qualified Infectious Disease Product Designation for AR-301 is a significant regulatory milestone for Aridis Pharmaceuticals. This designation often leads to increased investor confidence, which can result in a rise in stock prices.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100